Company: SHPH
Filing Date: 2025-04-21
Form Type: DEFR14A
Source: 0001641172-25-005474
Chunk: 4

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-04-21
Form: DEFR14A
Chunk 4
---
 for Ropidoxuridine and RT, for marketing and advertising
services, and for working capital and general corporate purposes.

OUR WORK. OUR PURPOSE.

At Shuttle Pharma, our mission is to launch the next generation of drugs to improve outcomes and achieve more cures for cancer patients undergoing
radiation treatments. We acknowledge that this will not be an easy task and will require dedication, extreme effort, and expertise.

Through teamwork and
strategic collaboration, we believe in our ability to make a meaningful difference in the lives of cancer patients. By pushing scientific boundaries and working together, we aim to
improve the lives of millions impacted by cancer and bring hope to patients and families around the world.

I thank our team and investors for continued support as Shuttle Pharma’s drugs achieve scientific milestones on a path
to commercialization and clinical application.

Sincerely yours,

/s/ Anatoly Dritschilo

Anatoly Dritschilo,
MD
Chairman of the Board of Directors

Shuttle Pharmaceuticals Holdings, Inc.

Notice of Annual Meeting of Stockholders of Shuttle Pharmaceuticals Holdings, Inc.

| ITEMS                                                                                                                             
 OF BUSINESS                                                                                                                       
 Proposal                                                                                                                          
 No. 1: Elect five (5) directors named in the attached Proxy Statement to serve until the 2026 Annual Meeting of Stockholders.     
 Proposal                                                                                                                          
 No. 2: To ratify appointment of Forvis Mazars, LLP as the Company’s independent auditor for the fiscal year ending                
 December 31, 2025.                                                                                                                |     | BOARD                 
 VOTING RECOMMENDATION 
 FOR                   
 each director nominee 
 FOR                   |
|:----------------------------------------------------------------------------------------------------------------------------------|:----|:----------------------|
| Proposal                                                                                                                          
 No. 3: To approve (on an advisory basis) the Company’s executive compensation.                                                    |     | FOR                   |
| Proposal                                                                                                                          
 No. 4: To authorize the Board of Directors to amend the Company’s amended and restated certificate of incorporation to            
 effect a reverse stock split of the Company’s issued and outstanding common stock by a ratio in the range of 1-for-3 to 1-for-100 
 (the “Reverse Stock Split”), to be effectuated at the Board’s discretion when and as needed.                                      |     | FOR                   |
| Proposal No. 5: To approve the first amendment to the Shuttle                                                                     
 Pharmaceuticals Holdings, Inc. 2018 Equity Incentive Plan to increase the amount of shares reserved for issuance by               
 5,000,000